Literature DB >> 17005663

Diminished production of monocyte proinflammatory cytokines during human immunodeficiency virus viremia is mediated by type I interferons.

John C Tilton1, Alison J Johnson, Marlise R Luskin, Maura M Manion, Jun Yang, Joseph W Adelsberger, Richard A Lempicki, Claire W Hallahan, Mary McLaughlin, Joann M Mican, Julia A Metcalf, Christiana Iyasere, Mark Connors.   

Abstract

The effect of human immunodeficiency virus (HIV) infection and high-level HIV replication on the function of monocytes was investigated. HIV-positive patients had elevated levels of spontaneous production of some or all of the monocyte proinflammatory cytokines measured (interleukin-1beta [IL-1beta], IL-6, and tumor necrosis factor alpha [TNF-alpha]) compared to uninfected controls. In patients on therapy with high frequencies of monocytes producing proinflammatory cytokines, this frequency was diminished in the context of viremia during an interruption of therapy. Diminished production of proinflammatory cytokines during viremia was restored by culture with autologous CD4(+) T cells or monocytes from an on-therapy time point or lipopolysaccharide (LPS). Microarray analysis demonstrated that diminished monocyte production of proinflammatory cytokines was correlated with elevated type I interferon-stimulated gene transcripts. The addition of exogenous alpha 2A interferon diminished the spontaneous production of IL-1beta, IL-6, and TNF-alpha but did not affect responses to LPS, recapitulating the changes observed for HIV-viremic patients. These results suggest that monocyte function is diminished during high-level HIV viremia and that this effect is mediated by chronic stimulation by type I interferons. This effect on monocytes during viremia may play a role in diminished innate or adaptive immune system functions in HIV-infected patients. In addition, the restoration of these functions may also play a role in some immune reconstitution syndromes observed during initiation of therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005663      PMCID: PMC1642603          DOI: 10.1128/JVI.00324-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  The nature of the principal type 1 interferon-producing cells in human blood.

Authors:  F P Siegal; N Kadowaki; M Shodell; P A Fitzgerald-Bocarsly; K Shah; S Ho; S Antonenko; Y J Liu
Journal:  Science       Date:  1999-06-11       Impact factor: 47.728

2.  Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors.

Authors:  J C Gea-Banacloche; S A Migueles; L Martino; W L Shupert; A C McNeil; M S Sabbaghian; L Ehler; C Prussin; R Stevens; L Lambert; J Altman; C W Hallahan; J C de Quiros; M Connors
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

3.  Deleterious effect of HIV-1 plasma viremia on B cell costimulatory function.

Authors:  Angela Malaspina; Susan Moir; Shyamasundaran Kottilil; Claire W Hallahan; Linda A Ehler; Shuying Liu; Marie A Planta; Tae-Wook Chun; Anthony S Fauci
Journal:  J Immunol       Date:  2003-06-15       Impact factor: 5.422

4.  Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART).

Authors:  C M Gray; J Lawrence; J M Schapiro; J D Altman; M A Winters; M Crompton; M Loi; S K Kundu; M M Davis; T C Merigan
Journal:  J Immunol       Date:  1999-02-01       Impact factor: 5.422

5.  CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+ CD38- CD8+ cells is associated with subsequent stable CD4+ cell levels. The Multicenter AIDS Cohort Study Group.

Authors:  J V Giorgi; H N Ho; K Hirji; C C Chou; L E Hultin; S O'Rourke; L Park; J B Margolick; J Ferbas; J P Phair
Journal:  J Infect Dis       Date:  1994-10       Impact factor: 5.226

6.  Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART.

Authors:  S F Stone; P Price; N M Keane; R J Murray; M A French
Journal:  HIV Med       Date:  2002-01       Impact factor: 3.180

7.  Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients.

Authors:  Anne Bourgarit; Guislaine Carcelain; Valerie Martinez; Caroline Lascoux; Veronique Delcey; Brigitte Gicquel; Eric Vicaut; Philippe H Lagrange; Daniel Sereni; Brigitte Autran
Journal:  AIDS       Date:  2006-01-09       Impact factor: 4.177

8.  Reduced ecto-5'-nucleotidase activity and enhanced OKT10 and HLA-DR expression on CD8 (T suppressor/cytotoxic) lymphocytes in the acquired immune deficiency syndrome: evidence of CD8 cell immaturity.

Authors:  J F Salazar-Gonzalez; D J Moody; J V Giorgi; O Martinez-Maza; R T Mitsuyasu; J L Fahey
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

9.  Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV.

Authors:  J A Kovacs; R A Lempicki; I A Sidorov; J W Adelsberger; B Herpin; J A Metcalf; I Sereti; M A Polis; R T Davey; J Tavel; J Falloon; R Stevens; L Lambert; R Dewar; D J Schwartzentruber; M R Anver; M W Baseler; H Masur; D S Dimitrov; H C Lane
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

10.  Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders.

Authors:  H E Heslop; A C Bianchi; F T Cordingley; M Turner; W Chandima; C P De Mel; A V Hoffbrand; M K Brenner
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

View more
  44 in total

1.  HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells.

Authors:  Marta Catalfamo; Michele Di Mascio; Zonghui Hu; Sharat Srinivasula; Vishakha Thaker; Joseph Adelsberger; Adam Rupert; Michael Baseler; Yutaka Tagaya; Gregg Roby; Catherine Rehm; Dean Follmann; H Clifford Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-05       Impact factor: 11.205

2.  Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s.

Authors:  Charles S Venuto; Jihoon Lim; Susan Messing; Peter W Hunt; Grace A McComsey; Gene D Morse
Journal:  Antivir Ther       Date:  2018

3.  A compendium of monocyte transcriptome datasets to foster biomedical knowledge discovery.

Authors:  Darawan Rinchai; Sabri Boughorbel; Scott Presnell; Charlie Quinn; Damien Chaussabel
Journal:  F1000Res       Date:  2016-03-07

4.  Prolonged activation of innate antiviral gene signature after childbirth is determined by IFNL3 genotype.

Authors:  Aryn A Price; Dana Tedesco; Mona R Prasad; Kimberly A Workowski; Christopher M Walker; Mehul S Suthar; Jonathan R Honegger; Arash Grakoui
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-06       Impact factor: 11.205

Review 5.  Cognitive consequences of a sustained monocyte type 1 IFN response in HIV-1 infection.

Authors:  Lynn Pulliam
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

6.  Desensitization to type I interferon in HIV-1 infection correlates with markers of immune activation and disease progression.

Authors:  Gareth A D Hardy; Scott F Sieg; Benigno Rodriguez; Wei Jiang; Robert Asaad; Michael M Lederman; Clifford V Harding
Journal:  Blood       Date:  2009-03-19       Impact factor: 22.113

7.  Circulating monocytes in HIV-1-infected viremic subjects exhibit an antiapoptosis gene signature and virus- and host-mediated apoptosis resistance.

Authors:  Malavika S Giri; Michael Nebozyhn; Andrea Raymond; Bethsebah Gekonge; Aidan Hancock; Shenoa Creer; Calen Nicols; Malik Yousef; Andrea S Foulkes; Karam Mounzer; Jane Shull; Guido Silvestri; Jay Kostman; Ronald G Collman; Louise Showe; Luis J Montaner
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

Review 8.  The macrophage: the intersection between HIV infection and atherosclerosis.

Authors:  Suzanne M Crowe; Clare L V Westhorpe; Nigora Mukhamedova; Anthony Jaworowski; Dmitri Sviridov; Michael Bukrinsky
Journal:  J Leukoc Biol       Date:  2009-12-01       Impact factor: 4.962

9.  Variability in drug metabolizing enzyme activity in HIV-infected patients.

Authors:  Amanda E Jones; Kevin C Brown; Rebecca E Werner; Karl Gotzkowsky; Andrea Gaedigk; Mike Blake; David W Hein; Charles van der Horst; Angela D M Kashuba
Journal:  Eur J Clin Pharmacol       Date:  2010-01-19       Impact factor: 2.953

10.  Virus-encoded TLR ligands reveal divergent functional responses of mononuclear phagocytes in pathogenic simian immunodeficiency virus infection.

Authors:  Elizabeth R Wonderlich; Viskam Wijewardana; Xiangdong Liu; Simon M Barratt-Boyes
Journal:  J Immunol       Date:  2013-01-21       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.